Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Rating of “Moderate Buy” from Analysts

Spruce Biosciences, Inc. (NASDAQ:SPRB) has been given a consensus recommendation of “Moderate Buy” by the twelve analysts that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have assigned a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $159.50.

A number of equities research analysts have issued reports on SPRB shares. Oppenheimer reiterated an “outperform” rating on shares of Spruce Biosciences in a research note on Wednesday, May 27th. The Goldman Sachs Group raised Spruce Biosciences to an “overweight” rating in a research note on Thursday, August 13th. Citizens Jmp cut their target price on Spruce Biosciences from $150.00 to $144.00 and set a “market outperform” rating for the company in a research report on Thursday, August 13th. Guggenheim reiterated a “buy” rating and set a $104.00 target price (down from $123.00) on shares of Spruce Biosciences in a research report on Monday, August 17th. Finally, HC Wainwright reissued a “buy” rating on shares of Spruce Biosciences in a research note on Wednesday.

Key Spruce Biosciences News

Here are the key news stories impacting Spruce Biosciences this week:

• Positive Sentiment: An analyst backed Spruce Biosciences following signs of regulatory progress, improving investor confidence in the company’s development and approval prospects. Spruce Biosciences stock gains after analyst backs regulatory progress
• Positive Sentiment: Oppenheimer maintained its Buy rating on Spruce Biosciences, signaling continued confidence in the company’s long-term outlook. No change to a price target was provided in the available report. Oppenheimer Sticks to Its Buy Rating for Spruce Biosciences
• Positive Sentiment: HC Wainwright raised its EPS estimates for 2027: Q1 to $(3.68) from $(3.92), Q2 to $(3.37) from $(3.58), Q3 to $(2.13) from $(2.26), and full-year 2027 to $(8.52) from $(9.09). The revisions imply expectations for smaller losses than previously forecast and were accompanied by a reiterated Buy rating.
• Neutral Sentiment: The analyst outlook remains mixed. HC Wainwright expects a substantial reduction in losses by 2027, but Spruce is still projected to report negative EPS in every listed period.
• Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate to $(5.13) from $(4.81) and its FY2026 estimate to $(23.32) from $(22.16), indicating weaker near-term earnings expectations. The company also recently reported a quarterly loss that missed consensus estimates, keeping profitability a significant risk.

Institutional Investors Weigh In On Spruce Biosciences

Hedge funds have recently made changes to their positions in the stock. AWM Investment Company Inc. purchased a new position in shares of Spruce Biosciences in the second quarter valued at approximately $7,937,000. Bank of New York Mellon Corp acquired a new stake in shares of Spruce Biosciences during the second quarter worth about $366,000. Cable Car Capital LP purchased a new position in shares of Spruce Biosciences in the third quarter valued at approximately $239,000. Stempoint Capital LP acquired a new position in shares of Spruce Biosciences in the first quarter valued at approximately $416,000. Finally, ADAR1 Capital Management LLC increased its stake in Spruce Biosciences by 1.0% during the 1st quarter. ADAR1 Capital Management LLC now owns 58,600 shares of the company’s stock worth $3,830,000 after buying an additional 600 shares during the period. 91.71% of the stock is currently owned by hedge funds and other institutional investors.

Spruce Biosciences Price Performance

Shares of NASDAQ SPRB opened at $60.78 on Monday. The company has a current ratio of 9.23, a quick ratio of 9.23 and a debt-to-equity ratio of 0.05. The business has a 50-day moving average of $49.83 and a 200-day moving average of $55.32. The firm has a market capitalization of $174.44 million, a price-to-earnings ratio of -1.53 and a beta of 3.23. Spruce Biosciences has a 12 month low of $7.00 and a 12 month high of $240.00.

Spruce Biosciences (NASDAQ:SPRB) last released its earnings results on Wednesday, August 12th. The company reported ($6.68) EPS for the quarter, missing analysts’ consensus estimates of ($5.79) by ($0.89). Sell-side analysts expect that Spruce Biosciences will post -25.53 earnings per share for the current fiscal year.

Spruce Biosciences Company Profile

Spruce Biosciences, Inc is a clinical-stage biopharmaceutical company dedicated to developing therapies for rare endocrine and dermatological disorders. Headquartered in San Diego, California, Spruce focuses on conditions with significant unmet medical needs, employing a precision medicine approach to identify and advance treatment candidates through late-stage clinical trials.

The company’s lead asset, tildacerfont, is an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist being evaluated for the treatment of congenital adrenal hyperplasia (CAH), a genetic disorder characterized by insufficient cortisol production and excess androgen levels.